Irinotecan

• Description:

  Irinotecan ((+) -Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].

• Product Name Alternative:

  (+) -Irinotecan; CPT-11; VAL-413 (free base)

• UNSPSC:

  12352005

• Hazard Statement:

  H301

• Target:

  Autophagy; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Irinotecan.html

• Purity:

  99.97

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3

• Molecular Formula:

  C33H38N4O6

• Molecular Weight:

  586.68

• Precautions:

  H301

• References & Citations:

  [1]Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56 (3) :219-26.|[2]Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49 (4) :329-35. Epub 2002 Jan 30.|[3]Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53 (3) :261-6. Epub 2003 Dec 5.|[4]Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8 (1) :116.|[5]Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21 (2) :130-42.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  Topo I

• Citation 01:

  Acta Pharm Sin B. 2024 Apr;14 (4) :1677-1692.|Adv Sci (Weinh) . 2025 Jan 31:e2408845.|Adv Sci (Weinh) . 2025 May 8:e2500271.|Apoptosis. 2016 Feb;21 (2) :130-42. |Biochem Pharmacol. 2023 Oct:216:115752.|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 16:167471.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomaterials. 2022 Oct:289:121800.|Biomed Pharmacother. 2020 Aug;128:110262.|Biomed Pharmacother. 2023 Jul:163:114751.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Sep 17.|bioRxiv. 2025 Sep 21.|bioRxiv. 2025 Sep 26:2025.09.24.677357.|bioRxiv. 2019 Dec.|Cancer Cell. 2025 Sep 25:S1535-6108 (25) 00393-9.|Cancer Lett. 2023 Feb 1:554:216028.|Cancer Lett. 2026 Jan 28:638:218156.|Cell Biosci. 2023 Nov 25;13 (1) :215.|Cell Death Dis. 2019 Nov 25;10 (12) :887. |Cell Death Dis. 2024 Jun 15;15 (6) :417.|Cell Death Dis. 2025 Apr 5;16 (1) :253.|Cell Death Dis. 2025 Jan 18;16 (1) :28.|Cell Death Dis. 2025 Mar 12;16 (1) :170.|Cell Discov. 2022 Sep 14;8 (1) :92.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Med. 2024 Mar 19;5 (3) :101468.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell. 2022 Sep 1;185 (18) :3356-3374.e22.|Clin Cancer Res. 2023 Nov 14;29 (22) :4644-4659.|EBioMedicine. 2023 Jun:92:104594.|Eur J Pharm Biopharm. 2022 Feb:171:39-49.|Eur J Pharmacol. 2023 Jun 15:949:175718.|Food Hydrocoll Health. 2025 Jun.|Gastroenterology. 2021 Nov;161 (5) :1601-1614.e23.|Gene. 2019 Mar 10:688:1-6.|Genome Med. 2016 Oct 31;8 (1) :116.|Heliyon. 2023 Apr 27;9 (5) :e15805.|Int J Pharm. 2020 Jun 30:584:119337.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Pharm Pharmacol. 2023 Apr 7;75 (4) :523-532.|Life Sci. 2019 Aug 15:231:116529.|Lung Cancer. 2023 Apr:178:237-246.|Mol Biol Cell. 2023 May 1;34 (5) :ar47.|Mol Cancer Ther. 2021 Dec;20 (12) :2483-2494.|Mol Cancer. 2024 Apr 4;23 (1) :70.|Mol Ther Oncol. 2025 Nov 22.|Mol Cancer Res. 2020 Mar;18 (3) :414-423.|Patent. US20210009719A1.|Pharmacol Res. 2021 Jan;163:105232.|PLoS Biol. 2022 Feb 24;20 (2) :e3001517.|PLoS Pathog. 2020 Mar 24;16 (3) :e1008429.|Redox Biol. 2024 May 23:73:103207.|Res Sq. 2025 Nov 19:rs.3.rs-7682325.|Signal Transduct Target Ther. 2021 May 28;6 (1) :188.|Theranostics. 2019 May 31;9 (13) :3732-3753.|Acta Biomater. 2025 Aug 12:S1742-7061 (25) 00602-6.|Apoptosis. 2019 Apr;24 (3-4) :312-325.|BMC Med Genomics. 2025 Oct 30;18 (1) :172.|Cancer Cell. 2025 Jul 14;43 (7) :1296-1312.e7.|Cancers (Basel) . 2023 Sep 6;15 (18) :4442.|Front Immunol. 2018 Jan 5:8:1919.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|NPJ Precis Oncol. 2025 Jul 1;9 (1) :207.|Oncogene. 2025 Jun;44 (22) :1678-1693.|Ruperto Carola University Heidelberg. Natural Sciences and Mathematics. 18 March 2022.|Sci Rep. 2024 Nov 26;14 (1) :29265.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.

• CAS Number:

  97682-44-5